American Capital Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
American Capital Advisory's VRTX Position: Q2 2026 in Review
American Capital Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 60% in Q2 2026, buying an estimated $2.66K and bringing the position to 16 shares worth $7.95K. The position accounts for ﹤0.01% of the portfolio, ranked #386.
American Capital Advisory first reported a position in VRTX in Q1 2025 and has held it in 6 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- American Capital Advisory held 16 shares of Vertex Pharmaceuticals worth $7.95K as of Q2 2026.
- American Capital Advisory bought 6 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.66K.
- Vertex Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #386 holding.
- American Capital Advisory first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
- 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.